#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

PACMAN-AMI trial: review of endpoints


Authors: Roman Margóczy 1,2
Authors‘ workplace: II. klinika kardiológie a angiológie, LF Slovenskej zdravotnickej univerzity, Bratislava 1;  Oddelenie funkčnej diagnostiky, Stredoslovenský ústav srdcových a cievnych chorôb, Banská Bystrica 2
Published in: AtheroRev 2022; 7(3): 156-158
Category: Clinical Studies

Overview

Timely addition of alirocumab to high-intensity statin therapy in patients with myocardial infarction resulted in lipid profile improvement and significantly greater percent atheroma volume regression, assessed by combination of three intracoronary imaging modalities.

Keywords:

alirocumab – fibrous cap thickness (FCT) – intravascular ultrasonography (IVUS) – maximal lipid core burden index (maxLCBI) – near infrared spectroscopy (NIRS) – optical coherence tomography (OCT) – percent atheroma volume (PAV)


Sources

1. Räber L, Ueki Y, Otsuka T et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA 2022; 327(18): 1771–1781. Dostupné z DOI: <http://10.1001/jama.2022.5218>.

Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adults
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#